| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2001: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2000: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Research Abstract |
1. The aim of die present study is to clarify whether the cross-talk between vitamin D and TGFβ signal Iransduclion pathways is operating in the pancreatic cancer cell lines. Pancreatic cancer cell line SUP-1, which well responds to both vitamin D and TGFβ, shows no expression of smad4 which acts at the terminal portion of TGFβ signal transduction pathways, suggesting that the cross-talk between vitamin D and TGFβ signal transduction pathways may be operating. However, no irancriptive activity of vitamin D receptor was observed in Die SUP-1 transfectecl by VDR response element after TGFβ treatment Accordingly, we cannot confirm he cross-talk between vitamin D and TGFβ signal transduction pathways.
2. The aim of this study is to assess whether the PPARg ligand, troglilazone, inhibits' the growth of pancreatic cancer cells., Troglilazone, had growth inhibitory, and differentiation induction effects on die pancreatic ameer cell lines.through the up-expression of p21, suggesting a new molecular target for effective therapy against pancreatic cancer.
3. Autoimmune pancreatitis is a distinctive disease entity characterized by high serum IgG4 concentrations, and we investigated the association between HLA alleles and autoimmune pancreatitis. The DRB1*0405-DQB1*0401 haplolype is significantly associated with autoimmune pancreatitis and may play a functional role in antigen presentation and the induction of an autoimmune response.
|
